Back to search

France· FR:62475406

ALHEMO 150 mg/1,5 mL, solution injectable en stylo prérempli

A concizumab product containing concizumab, registered in France by NOVO NORDISK (DANEMARK). The same ATC class is registered in 11 of our 19 countries.

ATC B02BX10

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedALHEMO 150 mg/1,5 mL, solution injec…ATCB02BX10REGISTER NO.FR:62475406PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Concizumab is registered in 11 of 19 countries.

Countries holding a registration under ATC B02BX10 (concizumab), each read from that country’s own register.

  • This record: France, from Base de données publique des médicaments — BDPM (France)
  • 8 of them publish a price we can compare per daily dose

Concizumab · ATC B02BX10

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of concizumab costs, country by country.

Normalised to the WHO defined daily dose (14 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Concizumab · price per daily dose (14 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1227.21
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
CONCIZUMAB
Manufacturer
NOVO NORDISK (DANEMARK)
Country
France (FR)
ATC code
B02BX10
ATC class
Concizumab
Defined daily dose
14 mg, P
Reimbursed
No
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

  • cip13
    3400930305119
    1 cartouche(s) en verre dans stylo pré-rempli de 1,5 ml

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Concizumab in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All concizumab products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Iceland · Alhemo
  • Norway · Alhemo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a65d931d-50cf-42d9-a185-7cae0da5ba2d
GET /v1/drugs/a65d931d-50cf-42d9-a185-7cae0da5ba2d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "62475406",
  "date_amm": "2024-12-13",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/24/1881",
  "substance": "CONCIZUMAB",
  "atc_source": "fr_atc_restore_2026-09-06",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "solution injectable",
  "voies_administration": "sous-cutanée",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}

See everything about concizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.